Rational application of gefitinib in NSCLC patients with sensitive EGFR mutations based on pharmacokinetics and metabolomics-Reference-Cited by-同舟云学术

Rational application of gefitinib in NSCLC patients with sensitive EGFR mutations based on pharmacokinetics and metabolomics

Published:2021-11-04 Issue: Volume: Page:
ISSN:1671-4083
Container-title:Acta Pharmacologica Sinica
language:en
Short-container-title:Acta Pharmacol Sin

Author:

Feng Wei,Chen Xi,Guan Shao-xing,Ruan Hong-lian,Huang Yan,Zhang Hui-zhen,Yang Yun-peng,Fang Wen-feng,Zhao Hong-yun,Zhuang Wei,Xin Shuang,Chen You-hao,Wang Fei,Gao Yue,Huang Min,Wang Xue-ding,Zhang Li

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Pharmacology,General Medicine

Link

https://www.nature.com/articles/s41401-021-00791-5.pdf

Reference23 articles.

1. Maemondo M, Inoue A, Kobayashi K, Sugawara S, Oizumi S, Isobe H, et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med. 2010;362:2380–8.

2. Fukuoka M, Yano S, Giaccone G, Tamura T, Nakagawa K, Douillard JY, et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial). J Clin Oncol. 2003;21:2237–46.

3. Frantz S. Iressa failure raises fears about accelerated approvals. Nat Rev Drug Discov. 2005;4:94–95.

4. Cohen MH, Williams GA, Sridhara R, Chen G, Pazdur R. FDA drug approval summary: gefitinib (ZD1839) (Iressa) tablets. Oncologist. 2003;8:303–6.

5. Cortot AB, Jänne PA. Molecular mechanisms of resistance in epidermal growth factor receptor-mutant lung adenocarcinomas. Eur Respir Rev. 2014;23:356–66.

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Targeted Inhibitors of EGFR: Structure, Biology, Biomarkers, and Clinical Applications;Cells;2023-12-25

2. Discovery of YS-363 as a highly potent, selective, and orally eﬃcacious EGFR inhibitor;Biomedicine & Pharmacotherapy;2023-11